SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Teva Pharmaceutical Industries Limited (TEVA) News

Follow Teva Pharmaceutical Industries Limited (TEVA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 81 public stories across 28 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol TEVA Asset equity Sector Markets 90 days 61 Last 42.62 Updated Nov 03, 2026, 09:14 PM UTC Open live news feed Open TEVA chart & news
M Teva Reports Third-Quarter 2026 Revenue of $4.4B, Net Income of $233M Revenue fell 1.9% from $4.48B a year earlier, while net income declined 46.2% and diluted EPS fell 45.9% to $0.2. EQUITY | Nov 03, 2026, 09:14 PM UTC M Teva reports sharp profit increase on strong branded-drug demand Teva, parent of Ratiopharm, reported a sharp increase in profit, citing strong demand for branded medicines. EARNINGS | Nov 03, 2026, 05:18 PM UTC M Teva Raises 2026 Revenue Forecast After Third-Quarter Profit Beat Teva reported higher-than-expected third-quarter profit, with branded-drug sales offsetting declines in generics, and raised its 2026 forecasts. EARNINGS | Nov 03, 2026, 04:32 PM UTC M Teva Reports Q3 Results and Raises 2026 Outlook Teva reported Q3 revenue of $4.395 billion and adjusted EPS of $0.86. It raised its 2026 revenue outlook to $16.7 billion–$17.0 billion and adjusted EPS guidance to $1.92–$2.11. EQUITY | Nov 03, 2026, 04:32 PM UTC M Teva Q3 Revenue Falls 2% to $4.4 Billion, Raises 2026 Brand Outlook Teva reported third-quarter 2026 revenue of $4.395 billion, down 2% year over year. Gross margin was 55.5%, net income attributable to Teva was $233 million and adjusted diluted EPS was $0.86. The company raised its 2026 EQUITY | Nov 03, 2026, 01:15 PM UTC M UZEDY Q3 U.S. Sales Rise 96% to $85M; 2026 Outlook Raised UZEDY U.S. net sales reached $85 million in Q3, up 96% year on year. The 2026 revenue outlook was raised. EARNINGS | Nov 03, 2026, 12:47 PM UTC M Teva Raises 2026 UZEDY Sales Forecast Teva raised its 2026 sales forecast for UZEDY. EARNINGS | Nov 03, 2026, 12:44 PM UTC M Teva Q3 Profit Rises More Than Expected on Strong Drug Sales Teva said strong sales of three of its own drugs offset declines in copycat medicines, driving a higher-than-expected rise in third-quarter profit. EQUITY | Nov 03, 2026, 12:26 PM UTC M Teva Q3 Adjusted Earnings Rise, Revenue Falls; 2026 Guidance Raised Teva Pharmaceutical Industries reported higher adjusted earnings and lower revenue for Q3, and raised its 2026 guidance. EQUITY | Nov 03, 2026, 12:20 PM UTC M Teva Posts Q3 Adjusted EPS of $0.86 per Share Teva’s Q3 adjusted EPS was $0.86 per share, versus a FactSet estimate of $0.72. EARNINGS | Nov 03, 2026, 12:06 PM UTC M Teva Reports Q3 Revenue of $4.40B vs. $4.23B Estimate EQUITY | Nov 03, 2026, 12:06 PM UTC M Teva Raises 2026 Outlook After 33% Growth in Key Brands Teva said its neuroscience portfolio is expanding through the Weltruza launch and the addition of BXCL-501. EARNINGS | Nov 03, 2026, 12:03 PM UTC L Teva to Halt Phase 2 Emrusolmin Trial Over Lack of Efficacy Teva Pharmaceuticals will halt its phase 2 TOPAS-M trial of the neurodegenerative drug emrusolmin over lack of efficacy. EQUITY | Nov 02, 2026, 01:55 PM UTC M Teva Acquires Worldwide Rights to BXCL501 for $57.5 Million Upfront Teva completed the asset acquisition, securing worldwide rights to BXCL501. The deal includes up to $67.5 million in potential contingent payments and received U.S. Bankruptcy Court approval. EQUITY | Oct 27, 2026, 04:02 PM UTC M Teva Acquires BioXcel Neuroscience Assets Through Court-Supervised Sale Teva acquired BioXcel’s neuroscience assets through a court-supervised sale process under the U.S. Bankruptcy Code. EQUITY | Oct 27, 2026, 12:06 PM UTC L Teva Pharmaceuticals Gets FDA Approval for Bone Drug as Biosimilar By Katherine HamiltonTeva Pharmaceuticals received approval from the Food and Drug Administration for its drug Degevma as a biosimilar to the bone-cancer treatment Xgeva.Degevma is indicated to prevent bone complications REGULATION | Sep 28, 2026, 08:56 PM UTC L Teva Pharmaceutical Industries Ltd. (TEVA) Wins FDA Nod For Xgeva Biosimilar Teva received FDA approval for DEGEVMA (denosumab-adet), a biosimilar to Xgeva, and plans to launch it alongside PONLIMSI in the U.S. in the coming months.Material DetailsContext by AI AnalystThis is a mid-cycle confirma REGULATION | Sep 28, 2026, 08:02 PM UTC H Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab) TEL AVIV, Israel, and PARSIPPANY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved DEGEVMA™ GEOPOLITICS | Sep 28, 2026, 08:02 PM UTC L Teva Pharmaceuticals: Compiled Document With Public Info Previously Provided by Teva to Assist Investors Ahead of 3Q Results, Expected to Be Released Nov 3 >TEVA Teva Pharmaceuticals: Compiled Document With Public Info Previously Provided by Teva to Assist Investors Ahead of 3Q Results, Expected to Be Released Nov 3 >TEVA NEWS | Sep 23, 2026, 08:53 PM UTC L Teva Pharmaceuticals: Releases 3Q 2026 Aide Memoire Teva Pharmaceuticals: Releases 3Q 2026 Aide Memoire NEWS | Sep 23, 2026, 08:53 PM UTC L TEVA - Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET TEVA - Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET EARNINGS | Sep 23, 2026, 08:45 PM UTC L TEVA - Teva Releases Q3 2026 Aide Memoire TEVA - Teva Releases Q3 2026 Aide Memoire NEWS | Sep 23, 2026, 08:45 PM UTC L Teva Pharmaceuticals Price Target Announced at $50.00/Share by Oppenheimer Ratings actions from Benzinga: GMT) Teva Pharmaceuticals Initiated at Outperform by OppenheimerRatings actions from Benzinga NEWS | Sep 23, 2026, 12:19 PM UTC M Teva issues about $4.9B in notes; shifts ADS to NYSE Teva Pharmaceutical Industries is refinancing debt with roughly $4.9B/€1.5B in notes and converting its ADS into ordinary shares for NYSE trading. MNA | Sep 21, 2026, 11:29 AM UTC L TEVA - New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients TEVA - New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients NEWS | Sep 18, 2026, 08:32 PM UTC L Teva posts Phase 3 post hoc data on olanzapine LAI Teva reported post hoc analyses from the Phase 3 SOLARIS trial on once-monthly subcutaneous olanzapine LAI TEV-749, including stabilization and low relapse rates, and data supporting direct switching from oral or short-a EQUITY | Sep 18, 2026, 08:31 PM UTC L TEVA - Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs TEVA - Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs NEWS | Sep 18, 2026, 08:31 PM UTC L TEVA - Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults TEVA - Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults NEWS | Sep 18, 2026, 08:30 PM UTC M Delhi High Court quashes Teva tax case, orders 783 cr refund The Delhi High Court quashed more than a decade-old tax proceedings against Teva Pharmaceutical Industries and its US affiliate tied to a Ranbaxy Laboratories deal, and reprimanded tax authorities for withholding a 783 c EQUITY | Sep 17, 2026, 04:17 AM UTC M Teva issues €1 bln of 4.250% senior notes due 2033 Teva Pharmaceutical Finance Netherlands II has issued EUR 1.0 billion of 4.250% senior notes due 2033. RATES | Sep 16, 2026, 08:39 PM UTC H Teva issues multi-tranche notes worth $3.2B and €1.5B Teva completed a multi-currency senior unsecured notes offering totaling $3.2 billion and €1.5 billion to refinance debt and enhance financial flexibility. EQUITY | Sep 16, 2026, 08:33 PM UTC L TEVA - Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care TEVA - Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care NEWS | Sep 16, 2026, 12:00 PM UTC H Delhi HC orders tax dept to refund Rs.783 cr to Teva Israel over Ranbaxy payment New Delhi, Sept. 15 -- The Delhi High Court on Tuesday quashed tax proceedings against Israeli drugmaker Teva Pharmaceutical Industries Ltd. and its US affiliate arising from a deal with Ranbaxy Laboratories, and ordered GEOPOLITICS | Sep 15, 2026, 02:22 PM UTC H Teva's Shares Now Trade Directly on the NYSE — Here's What Else Changed Teva Pharmaceutical Industries Ltd. (NYSE: TEVA ) had a busy week that included a major debt refinancing, a milestone shift in how its shares trade on the NYSE and analyst activity. Teva stock is trading near recent high LIVE | Sep 15, 2026, 12:49 PM UTC L Teva begins NYSE trading of ordinary shares as ADS program terminates Teva began trading its ordinary shares on the New York Stock Exchange and terminated its ADS program.Key Highlights:Original SEC Filing: TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ] - 8-K - Sep. 14, 2026This is an AI-powe REGULATION | Sep 14, 2026, 08:15 PM UTC L Teva prices $4.9bn equivalent senior notes, issues five tranches maturing 2032—2037 Teva priced approximately $4.9 billion (equivalent) of senior notes across five tranches and expects settlement on or about September 16, 2026.Key Highlights:Original SEC Filing: TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA REGULATION | Sep 11, 2026, 08:13 PM UTC L Teva prices $4.9B senior notes to refinance higher-cost debt MACRO | Sep 10, 2026, 10:51 AM UTC L Teva prices $4.9 billion-equivalent senior notes EQUITY | Sep 10, 2026, 10:04 AM UTC L Leerink Partners sets Teva price target at $45 Leerink Partners announced a $45.00 per-share price target for Teva. EQUITY | Sep 09, 2026, 03:50 PM UTC H S&P upgrades Teva to BBB- as MFN talks and notes plan progress Teva Pharmaceutical Industries Ltd (TEVA) gained investment-grade status after S&P upgraded it to BBB-. Teva also joined nine drugmakers in MFN talks tied to at least $19.6B in U.S. manufacturing investment and plans EUR EQUITY | Sep 07, 2026, 11:23 AM UTC L Teva launches senior notes offering Teva announced the launch of an offering of senior notes. EQUITY | Sep 07, 2026, 07:53 AM UTC L UBS maintains Buy rating on Teva Pharmaceuticals UBS maintained a Buy rating on Teva Pharmaceuticals, according to Benzinga ratings actions. EQUITY | Sep 04, 2026, 06:43 PM UTC L S&P Global Ratings upgrades Teva to BBB S&P Global Ratings upgraded Teva’s credit rating to BBB-. The move marks the third credit rating upgrade in recent months. EQUITY | Sep 04, 2026, 03:30 PM UTC M TEVA’s TEV-408 shows favorable phase II-A celiac results TEV-408, an anti-IL-15 antibody, demonstrated statistically and clinically meaningful gut-architecture protection and inflammation reduction in a phase II-A celiac disease study, with favorable safety and symptom trends. EQUITY | Sep 02, 2026, 02:20 PM UTC M TEVA’s TEV-408 posts robust phase IIa celiac results TEVA’s anti-IL-15 antibody TEV-408 showed statistically and clinically significant gut-architecture protection and reduced inflammation in a phase IIa celiac disease study, with a favorable safety profile and symptom-imp EQUITY | Sep 02, 2026, 01:27 PM UTC M Teva’s celiac drug meets main goal in mid-stage trial Teva said its experimental immune-disorder drug helped prevent gluten-related intestinal damage in adults with celiac disease, meeting the main goal of its mid-stage trial. U.S.-listed shares were up over 4% in premarket EQUITY | Sep 02, 2026, 12:02 PM UTC M TEVA’s TEV-408 posts positive Phase 2a topline in celiac disease TEV-408 (anti-IL-15) reported positive Phase 2a topline results in celiac disease, including prevention of gluten-induced intestinal damage and improved symptoms after a single subcutaneous dose. EQUITY | Sep 02, 2026, 11:16 AM UTC M Teva’s TEV ‘408 meets Phase 2a celiac primary endpoint A Phase 2a study of TEV ‘408 in celiac disease met its primary endpoint, showing significant prevention of gluten-induced intestinal damage and favorable effects on inflammation and symptoms. Drug was well-tolerated. EQUITY | Sep 02, 2026, 11:16 AM UTC M Teva reports positive Phase 2a topline celiac disease results Teva said its Phase 2a study in celiac disease for its anti-IL-15 antibody delivered positive topline results, further validating its pipeline-in-a-product potential. EQUITY | Sep 02, 2026, 11:03 AM UTC L TEVA - Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September TEVA - Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September EQUITY | Sep 01, 2026, 08:30 PM UTC L White House deal targets lower US drug prices via $19.6B infusion White House deal with mid-size drugmakers includes a $19.6B infusion into US plants aimed at lowering drug prices. GEOPOLITICS | Aug 31, 2026, 10:44 PM UTC L Trump announces drug pricing deals with Teva and 8 others TradingView News reports that Trump announced drug pricing deals with Teva and eight other companies. EQUITY | Aug 31, 2026, 09:53 PM UTC L Trump Administration Reaches Most-Favored-Nation Drug Pricing Deals With 9 Companies Trump Administration Reaches Most-Favored-Nation Drug Pricing Deals With 9 Companies GEOPOLITICS | Aug 31, 2026, 08:45 PM UTC L TEVA and Trump Administration plan agreement on affordable medicines TEVA says it and the Trump Administration intend to reach an agreement on affordable medicines and U.S. supply-chain security for patients. EQUITY | Aug 31, 2026, 08:06 PM UTC H BioXcel files Chapter 11, names Teva stalking horse bidder BioXcel Therapeutics began voluntary Chapter 11 proceedings and entered an asset sale agreement with Teva Pharmaceuticals International GmbH, with Teva set as stalking horse bidder in a court-supervised auction. RATES | Aug 28, 2026, 03:06 PM UTC L Teva Sinks on Bid to Buy BioXcel Teva Sinks on Bid to Buy BioXcel EQUITY | Aug 28, 2026, 01:56 PM UTC M Teva proposes acquisition of novel neuroscience product Teva announced a proposed acquisition of a novel neuroscience product. MNA | Aug 28, 2026, 12:04 PM UTC H BioXcel files for bankruptcy, agrees asset sale to Teva BioXcel filed for bankruptcy and agreed to sell assets to Teva. EQUITY | Aug 28, 2026, 10:30 AM UTC M Teva announces proposed acquisition of novel neuroscience product Teva says it has proposed an acquisition of a novel neuroscience product as part of its pivot to a growth strategy. MNA | Aug 28, 2026, 10:17 AM UTC M Aurinia says Teva generic voclosporin may launch after 2036 Aurinia Pharmaceuticals says Teva may launch a generic version of voclosporin in the U.S. no earlier than December 7, 2036, while patent litigation continues in New Jersey. REGULATION | Aug 19, 2026, 08:06 PM UTC